



Fri Dec 15 10:49:36 2006

To: Patrick Reynolds, M.D.
Eric Bubbers, Ph.D.
HEMATOLOGY/ONCOLOGY

cc: John Hull
MATERIALS MANAGEMENT ADMINISTRATION
Elaine Verdugo
HEALTH INFORMATION MANAGEMENT ADMINISTRATION

From: Alan B. Lewis, M.D.
Vice-Chair, Committee on Clinical Investigations, MS# 23

Re: CCI-05-00051 Patrick Reynolds, M.D.
Expanded Access Protocol for Purging of Peripheral Blood Stem Cells or Bone Marrow from
Patients with High-Risk Neuroblastoma Prior to Autologous Transplantation Under FDA
Investigational Device Exemption BB-IDE-2259

CCI AMENDMENT APPROVAL DATE: 12/13/2006

NOTICE OF APPROVAL OF AMENDMENT

(CCI Reference: November 2006 amendment - CCI-05-00051-AM005)

Dear Dr. Reynolds,

Thank you for the submission of the above-named amendment. The amendment was created to make changes requested by the CCI after the review of the progress report. The amendment is now approved and the progress report is ready for approval. The final formal approval letter will be sent out to you soon with the approval of the progress report.

If you have any questions or comments, please do not hesitate to contact the CCI Office or me at ext. 2265. Thank you very much for helping to protect the rights and welfare of human research subjects at Childrens Hospital Los Angeles.

This is an auto-generated email. Please do not respond directly to this message using the "reply" address. A response sent in this manner cannot be answered. If you have further questions, please contact your IRB Administrator or IRB/CCI office.

The contents of this email are confidential and intended for the specified recipients only. If you have received this email in error, please notify istar@usc.edu and delete this message.

MEMORANDUM

TO: Participating investigators
FROM: Judith Villablanca, MD
C. Patrick Reynolds, MD, PhD
DATE: December 15, 2006

RE: CCI# 05.0005: Expanded Access Protocol for Purging of Peripheral Blood Stem Cells or Bone Marrow from Patients with High-Risk Neuroblastoma Prior to Autologous Transplantation Under FDA Investigational Device Exemption BB-IDE-2259

STUDY AMENDMENT (NOVEMBER 2006 [CCI 05-00051-AM005]): Protocol version date 12-8-06

Type of changes included in this amendment:

- Administrative changes
- Informed consent changes

Please note that IRB approval of the amendment is required prior to entering further patients.

The protocol was amended to the version dated 12-8-06 with the following specific changes. The revised protocol and sample consent are posted on the website at www.purging.nant.org (both track changes version and changes accepted version).

1. CHANGES TO THE SAMPLE INFORMED CONSENT

- 1.1 Under the Section "**Potential Risks and Discomforts**" the paragraph regarding application of California Choice of Law was amended based on recommendations from OHRP to amend the wording of this section to eliminate possibly exculpatory language regarding utilizing California law for disputes/claims regarding purging. The amended paragraph was also moved to the end of the Risks Section (previously this paragraph was at the beginning of this section).

The previous language was:

Childrens Hospital Los Angeles takes all possible precautions to protect your stem cells from damage during testing, purging, storage and shipping. However, if there is ever any dispute or claim related to the testing, purging, storage and/or shipping of your stem cells by Childrens Hospital Los Angeles, you agree that the dispute or claim will be decided under California law, regardless of where you may live.

The language was amended to the following:

Childrens Hospital Los Angeles takes all possible precautions to protect your stem cells from damage during testing, purging, storage and shipping. If there is ever any dispute or claim related to the testing, purging, storage and/or shipping of your stem cells by Childrens Hospital Los Angeles, Childrens Hospital Los Angeles will try to have the dispute or claim decided under California law, regardless of where you may live

Please submit this amended consent to your IRB. If recommended by your local IRB, patients who have already been consented at your institution will be reconsented with the revised consent. Your IRB approval of the revised consent must be submitted to CHLA

before you can enter further patients on this compassionate study. The IRB approval must include a statement regarding whether it will be required to re-consent patients with the 12-8-06 version.

- 1.2 The "**Witness**" **Signature Block** was changed to "Interpreter" .
- 1.3 The section **FINANCIAL INTEREST OF THE INVESTIGATOR** was amended to clarify this issue.

The section previously read:

Compensation of the investigators is *not* based upon the number of subjects enrolled. If your physician is an investigator for this study, s/he is interested in both your healthcare, and the conduct of this compassionate research study. You are not under any obligation to participate in a compassionate research study conducted by your doctor. There are no patents held by CHLA or the investigators that would benefit from this study.

The section now reads:

You are not under any obligation to participate in a compassionate research study conducted by your doctor. Childrens Hospital Los Angeles does receive a fee for the purging of your stem cells. Dr. Patrick Reynolds at Childrens Hospital Los Angeles developed the purging process. The patent for the purging device is held by the United States Navy.

- 1.4 The CHLA Bill of Rights was deleted from the Sample consent in the protocol.
- 1.5 A statement was added under "**POTENTIAL RISKS AND DISCOMFORTS**" that if the risks occurred, it is possible the stem cells may need to be collected again.

2. CHANGES TO THE PROTOCOL

- 2.1 The **version of the protocol** document was changed to **12-8-06**.
- 2.2. **APPENDIX V: PROCEDURE FOR IMMUNOLOGIC PURGING OF MARROW AND PBSC PRODUCT** was updated to reflect the current standard procedures for immunocytologic testing of stem cells for tumor cells.

Please submit the amended protocol to your IRB for review. IRB approval of this amendment is required prior to entering any further patients on this protocol. If you have any questions regarding this amendment, please contact Dr. Judy Villablanca at 323-669-5654 or jvillablanca@chla.usc.edu.